CoV Biotechnology
ExitedCoV Biotechnology is an early-stage Singapore-based biotechnology company focusing on inducing broad, pan-sarbecovirus immune responses to address the evolving and mutating nature of the coronavirus.
Singapore, Singaporewww.covbiotech.com ↗
Total raised
€0
€0
Funding rounds
0
Investors
0
distinct backers
Active since
—
Funding rounds
0 roundsNo funding rounds recorded.
Exit
Type
acquisition
Date
Jan 2025
Value
—
Acquiror
Leyden Labs (Netherlands)
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech
- Doctolib€734MFrance · E-commerce